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ABSTRACT
Medulloblastoma is the most common malignant brain cancer of childhood.
Further understanding of tumorigenic mechanisms may define new therapeutic
targets. Geminin maintains genome fidelity by controlling re-initiation of DNA
replication within a cell cycle. In some contexts, Geminin inhibition induces
cancer-selective cell cycle arrest and apoptosis and/or sensitizes cancer cells
to Topoisomerase IIα inhibitors such as etoposide, which is used in combination
chemotherapies for medulloblastoma. However, Geminin’s potential role in
medulloblastoma tumorigenesis remained undefined. Here, we found that Geminin
is highly expressed in human and mouse medulloblastomas and in murine granule
neuron precursor (GNP) cells during cerebellar development. Conditional Geminin
loss significantly enhanced survival in the SmoA1 mouse medulloblastoma model.
Geminin loss in this model also reduced numbers of preneoplastic GNPs persisting at
one postnatal month, while at two postnatal weeks these cells exhibited an elevated
DNA damage response and apoptosis. Geminin knockdown likewise impaired human
medulloblastoma cell growth, activating G2 checkpoint and DNA damage response
pathways, triggering spontaneous apoptosis, and enhancing G2 accumulation of cells
in response to etoposide treatment. Together, these data suggest preneoplastic and
cancer cell-selective roles for Geminin in medulloblastoma, and suggest that targeting
Geminin may impair tumor growth and enhance responsiveness to Topoisomerase
IIα-directed chemotherapies.

INTRODUCTION

of Cdt1 becomes active during S/G2 to prevent reinitiation
of DNA replication within a cell cycle, while Gmnn
proteolysis during mitosis enables initiation of a new
round of replication in the subsequent cell cycle [9].
Cells bypassing these controls accumulate DNA damage,
including >4N DNA content and stalled replication forks.
This can trigger G2 checkpoint arrest, which is frequently
followed by apoptosis.
Prior work comparing Gmnn requirements in
multiple cancer- and non-cancer-derived cell lines
suggested that some cancer cell lines are particularly
dependent upon levels of Gmnn activity and selectively

Initiation of DNA replication is a tightly controlled
process, involving formation of pre-replication complexes
(pre-RCs) on sites in the genome [1-3]. After initiation
of DNA replication, several convergent pathways
restrict additional pre-RC formation, limiting genome
duplication to once per cell division [4-9]. The primary
target of this regulation in most metazoan cells is Cdt1,
which is inactivated by mechanisms involving either Cdt1
proteolysis or inhibitory interaction with the nucleoprotein
Geminin (Gmnn) [1, 2, 4, 7, 9]. Gmnn-mediated inhibition
www.impactjournals.com/Genes&Cancer
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sensitive to Gmnn inhibition, exhibiting re-replication,
G2 checkpoint activation, and apoptosis under conditions
where Gmnn-deficient non-cancer cell lines are unaffected
[10]. This cancer cell sensitivity to Gmnn loss may
involve greater relative ability of non-cancer cell lines
to use alternate molecular mechanisms to control Cdt1
activity by proteolysis, and/or relative over-expression of
Cdt1 and pre-RC proteins in many cancer cell contexts
[10, 11]. Based upon these results, it has been proposed
that small molecule inhibitors directed against Gmnn may
have utility as selective anticancer agents [10, 12].
Gmnn is over-expressed in many tumor types,
with high expression frequently serving as a diagnostic
criterion for aggressiveness and poor prognosis [13-21].
In addition to a role in maintaining genome fidelity, Gmnn
is required for several aspects of embryonic development,
and can control embryonic gene expression through
interactions with chromatin regulatory complexes [2235]. For example, Gmnn promotes neural fate acquisition
of embryonic stem cells [30, 36], while loss of Gmnn
function in the forming central nervous system from
embryonic day 8.0 (E8.0) in conditional mouse models
results in neural tube defects, at least in part through
failure to activate expression of genes that promote neural
tube patterning and neuronal differentiation [29].
Given Gmnn’s potential to selectively inhibit DNA
replication in other types of cancer, we hypothesized
that Gmnn could potentially modulate tumorigenesis in
medulloblastoma, the most common malignant pediatric
brain tumor and the leading cause of cancer-related death
in children. Medulloblastoma accounts for ~20% of all
malignant brain cancers of childhood [37]. Multi-modal
treatment including tumor resection, radiotherapy, and
adjuvant chemotherapy have improved long term eventfree survival for average risk patients, but outcomes
are inferior in children of <3 years or in patients with
tumor recurrence [37-39]. Further development of
targeted treatments is likely to emerge from an improved
understanding of the molecular mechanisms underlying
this disease. Therefore, here we used both mouse animal
and human cell models to study whether Gmnn could act
as a modifier of medulloblastoma tumorigenesis and to
begin to elucidate some of the underlying mechanisms.

we found that Gmnn expression is elevated in human
medulloblastomas, relative to normal cerebellum (Figure
1A). Human tumors with high Gmnn expression levels
also exhibit high levels of expression of genes associated
with the cell cycle, DNA damage/repair, and components
of the pre-replication complex (e.g. Ccnb1/b2, Cenpe/h,
Mcm6, Orc1/6)(Figure 1B-1C; Supplementary Table
1). Gmnn expression was most strongly anti-correlated
with terms associated with differentiated neural cells
(transmission of nerve impulse, neuropeptide signaling,
voltage-gated channel). All genes positively correlated
with Gmnn in human medulloblastoma and correlated and
anti-correlated GO terms are in Supplementary Tables 1-3.
These data are consistent with Gmnn being most highly
expressed in rapidly proliferating cells of the tumor and
anti-correlated with differentiated cells or brain regions.
Likewise, in a murine medulloblastoma model (SmoA1),
Gmnn and the proliferative cell marker Ki-67 were both
strongly expressed in tumor tissue, while neither marker
was expressed in adjacent normal brain tissue (Figure 1D).
Based upon genomic sequencing and expression
analysis, medulloblastomas have been divided into four
major molecular subgroups: Wnt, Sonic Hedgehog (Shh),
Group 3, and Group 4 [40-43]. We therefore examined
Gmnn expression levels in human medulloblastomas based
on molecular and histological subtypes, sex, and several
other criteria (presence of a β-catenin mutation, staging,
time of diagnosis), using two medulloblastoma expression
datasets. No subtype or sex-dependent differences in
Gmnn levels were seen, with the exception of lower
Gmnn levels in Wnt subtype tumors with monosomy 6,
consistent with the location of Gmnn on chromosome 6
(Supplementary Figure 1).

Geminin deficiency enhances survival in the
SmoA1 medulloblastoma model
About 30% of human medulloblastomas exhibit
constitutive Shh pathway activation [44], resulting from
either inactivating mutations in the negative regulators
Patched1 (Ptch1) or Suppressor of Fused (Sufu), or
from activating mutations in the signal transducing
receptor Smoothened (Smo) or amplification of the
Gli2 transcription factor [42, 45-47]. Formation of these
tumors involves abnormal development of granule
neuron precursors (GNPs) [48, 49]. Granule neurons are
the most abundant cerebellar neurons and develop from
committed GNPs, which migrate over the surface of the
developing cerebellum to form the external granule layer
(EGL) and undergo major expansion in the EGL during
the first two postnatal weeks of development in the mouse
[49, 50]. After this, they exit the cell cycle, differentiate,
and migrate through the adjacent Purkinje cell layer to
establish the internal granule layer (IGL) [48, 49].
In the mouse, Gmnn was previously shown to be
expressed in proliferating embryonic neural progenitors

RESULTS
Geminin is highly expressed in human and mouse
medulloblastoma
As Gmnn inhibition selectively impaired the growth
of several cancer cell lines under conditions where normal/
non-cancer lines were not affected [10], we hypothesized
that Gmnn inhibition might represent a therapeutic target
in medulloblastoma. Using publicly available data,
www.impactjournals.com/Genes&Cancer
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and adult neural stem cells, with downregulation of
Gmnn expression accompanying the transition from
progenitor to post-mitotic neuron [29, 51]. We examined
its expression in the developing cerebellum, and found
that Gmnn is highly expressed by GNPs in the EGL of
the murine neonatal cerebellum at postnatal day 5 (P5),
with expression overlapping Ki67, which marks all
proliferating cells (Figure 2A). As conditional loss of
Gmnn in the forming neural plate from ~E8.0 in the mouse
resulted in neural tube defects [29], we assessed later
neurodevelopmental requirements here by performing
Nestin-Cre-mediated conditional Gmnn excision. B6.CgTg(Nes-Cre)1Kln/J (Jax 003771; hereafter Nes-Cre) mice
express Cre recombinase under control of the rat nestin
promoter and enhancer, predominantly in neural stem
and progenitor cells of the central and peripheral nervous
system (CNS/PNS) from embryonic day 10.5. Using this
line, Gmnn protein levels in the CNS were previously
shown to be strongly reduced by E14.5 [52]. Congruent
with prior work [52], Nes-Cre; Gmnnfl/fl mice developed
into normal, fertile adults. As described in detail below

(Supplementary Figure 10), we further subjected these
animals to a battery of behavioral assays and found that
they exhibited no motor, cognitive, or other detectable
behavioral abnormalities, which was consistent with
prior work demonstrating a lack of neural stem cell or
neurogenesis defects in this model [52]. Therefore, we
used this model to test whether Gmnn deficiency could
modify medulloblastoma formation or progression, by
combining Nes-Cre mediated Gmnn excision with the
SmoA1 model of murine medulloblastoma. This mouse
model of the human SHH medulloblastoma subtype
expresses an activated form of Smoothened (SmoA1)
specifically in GNPs [53], under control of the NeuroD2
promoter (ND2) [54]. These mice exhibit excessive
GNP proliferation and 48% of the animals develop
medulloblastoma, with a median of 6 months of age [53].
We initially compared Gmnn expression levels in
GNPs prepared from SmoA1 versus wildtype cerebellum
at P6: Gmnn levels were elevated in SmoA1 transgenic
animals (both males and females), compared to wild-type
animals (Figure 2B). Cohorts of P14 male and female

Figure 1: Geminin is highly expressed in human and mouse medulloblastoma. (A) Elevated Gmnn expression was detected

in four human medulloblastoma microarray datasets relative to normal cerebellum. (B-C) Top genes (B) and gene ontology (GO) terms
(C) whose expression most strongly correlated with Gmnn expression were defined in 103 medulloblastoma samples (Northcott core
transcript; GSE21140) using R2 (see Methods). (D) Gmnn and Ki67 immunostaining of cerebellar sections from an adult SmoA1 mouse
with medulloblastoma. Boxed insets (right panels) at the tumor boundary (marked with arrowheads) show relative expression levels in
normal cerebellum (left) versus tumor (right) for Gmnn and Ki67. Scale bars= 500µm (left) and 100µm (right).
www.impactjournals.com/Genes&Cancer
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adults were then generated, all of which carried one
copy of the Nes-Cre and SmoA1 transgenes and were
either heterozygous or homozygous for the floxed Gmnn
allele. Western blotting for Gmnn levels in cerebellar
tissues from these SmoA1; Nes-Cre; Gmnnfl/fl animals
revealed complete loss of Gmnn protein by comparison
to their SmoA1; Nes-Cre; Gmnn+/fl littermates, which
retained Gmnn expression (Figure 2C). We tracked
cohorts of animals with these genotypes (n=14 animals
in each group; including males and females) for one year.
Adult SmoA1 mice that developed clinical symptoms of
medulloblastoma (enlarged posterior fossa, tilted head,
hunched posture, ataxia) were euthanized and histological
sectioning of the brain was performed to confirm the
presence of a tumor.
As seen previously for the SmoA1 medulloblastoma
model [53], ~50% of both males and females with a copy

of wild-type Gmnn developed tumors and did not survive
beyond 6 months. By contrast, animals homozygous for
the Gmnn floxed allele (SmoA1;Nes-Cre; Gmnnfl/fl) had
a substantial survival advantage, relative to SmoA1;NesCre;Gmnn+/fl animals that retained wild type Gmnn
function (Figure 2D). This effect was significant for both
males and females (Supplementary Figure 2), but was
more pronounced for males, with ~80% of the SmoA1;
Nes-Cre; Gmnnfl/fl animals surviving through the end of
the study. Upon histological sectioning, all symptomatic
animals exhibited large tumors that were usually detected
bilaterally in parasagital sections through the brain,
while very few animals that were asymptomatic through
the end of the study exhibited a visible tumor mass
(Supplementary Figure 3). We examined tumor size and
histology by hematoxylin-eosin staining and also analyzed
a subset of the tumors by immunofluorescence for Ki-67

Figure 2: Geminin loss of function enhances survival in the SmoA1 medulloblastoma model. (A) In the cerebellum of P5

mice, Gmnn is expressed in the EGL in a pattern like Ki67, which marks proliferative cells. Scale bar=100µm. (B) Gmnn mRNA levels
were defined by qRTPCR analysis in P6 GNP preparations from individual wild-type (n=4) versus SmoA1 transgenic males (n=2) and
females (n=5), and is expressed as a normalized fold difference. **p<0.01 was defined by two-tailed student’s t-test. ns=not significant. (C)
Gmnn protein levels in SmoA1; Nes-Cre; Gmnn+/fl versus Gmnnfl/fl cerebella at P14, defined by Gmnn immunoblotting with γTubulin as a
loading control. (D) Kaplan-Meier survival plot for cohorts of mice hemizygous for both the Nestin-Cre and SmoA1 transgenes and either
heterozygous or homozygous for the floxed Gem allele. Animals were euthanized when they exhibited neurologic impairment or morbidity
or at the end of the study and presence or absence of tumors was confirmed.
www.impactjournals.com/Genes&Cancer
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Figure 3: Geminin loss reduces numbers of persisting preneoplastic GNPs in SmoA1 transgenic mice. (A) Thickness

of the EGL layer in P14 cerebella hemizygous for the Nes-Cre and SmoA1 transgenes and heterozygous or homozygous for the Gmnn
floxed allele. Control comparison to animals not carrying the SmoA1 transgene is also shown. Matched cerebellar sections with insets
corresponding to labelled regions at right. (B) Quantitation for A, n=3 animals for each genotype, with matched 5µm sections analyzed for
each animal (see Methods) and the percentage of sections with >2-3 persisting EGL cell layers scored as thickened for 3 animals for each of
the three genotypes. (C) At P28, cerebella of the same genotypes as in A are shown, with pGNPs persisting at the cerebellar surface staining
darkly in the H&E stained brain sections (marked by arrowheads). (D) Averaged counts/section were from 4 matched serial sections per
P28 brain. Number of animals per genotype analyzed: n=11 (SmoA1; Nes-Cre; Gmnn+/fl), n=10 (SmoA1; Nes-Cre; Gmnnfl/fl), n=6 (NesCre; Gmnn+/fl). *<0.05, **<0.01 were defined by two-tailed student’s t-test.
www.impactjournals.com/Genes&Cancer
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and NeuN, marking proliferating and differentiated cells
in the tumor, respectively (Supplementary Figure 3). All
of these characteristics appeared similar in tumors with
either the SmoA1;Nes-Cre;Gmnn+/fl or SmoA1;Gmnnfl/
fl
genotypes. As tumors were processed for histology as
animals in the cohort became symptomatic, these data did
not reveal whether the rate of tumor growth was altered
by Gmnn deficiency. However, the size, histology, and
proliferative index of tumors that were analyzed did
not appear to differ by genotype, despite the survival
advantage conferred by Gmnn deficiency.

3A-3B). This phenotype was also seen in cerebellar
sections from SmoA1 transgenic animals at P16, with
increased EGL thickness apparent in SmoA1; Nes-Cre;
Gmnn+/fl animals by comparison with SmoA1; Nes-Cre;
Gmnnfl/fl animals (Supplementary Figure 4). These data
suggest that, relative to heterozygous animals expressing
Gmnn, loss of Gmnn results in fewer SmoA1 expressing
GNPs with preneoplastic potential remaining at the
cerebellar surface.
By four postnatal weeks (P28), the EGL has largely
disappeared (Figure 3C, Nes-Cre; Gmnn+/fl animal lacking
the SmoA1 transgene). However, in mice carrying the
SmoA1 transgene at this stage, foci of ectopic proliferative
preneoplastic GNPs (pGNPs) are still present on the
external cerebellar surface. These may be classified as
focal hyperplasias (<30 pGNPs) or diffuse hyperplasias
(>5000 cells). As many of these cells do not develop into
tumors, medulloblastoma incidence is influenced both by
the frequency with which GNPs become preneoplastic in
early postnatal life and with the survival, persistence, and
continued proliferation of these cells to form tumors. We
therefore generated sex-matched littermates that carried
one copy of the SmoA1 and Nestin-Cre transgenes and
were also either heterozygous or homozygous for the
floxed Gmnn allele, comparing cerebellar sections from
these animals at P28. Animals homozygous for Gmnn
loss (SmoA1; Nes-Cre; Gmnnfl/fl) had six-fold fewer
preneoplastic cells than SmoA1; Nes-Cre; Gmnn+/fl
animals retaining wild-type Gmnn (Figure 3C-3D, pGNP
cell counts for individual animals are in Supplementary
Figure 5). In addition, we found that some P28 SmoA1;
Nes-Cre; Gmnn+/fl animals had severe cerebellar dysplasia,
while we never observed this phenotype in SmoA1; NesCre; Gmnnfl/fl animals (Supplementary Figure 6). Together,
these data suggest that Gmnn deficiency alters the
proliferation, differentiation, and/or survival of pGNPs.
Therefore, we next assessed whether alteration of these
properties could account for the significant decrease
in pGNPs under conditions of Gmnn deficiency in the
SmoA1 transgenic model.

Geminin deficiency reduces the persistence of
preneoplastic cells in SmoA1 mice
The work above demonstrated that Gmnn deficiency
could enhance survival in a model of medulloblastoma
driven by constitutively active Shh signaling. Since
both Gmnn-expressing and Gmnn-deficient cells could
contribute to tumors, we examined whether the survival
advantage conferred by Gmnn deficiency might relate
to an altered propensity of preneoplastic cells to form
tumors. In mouse models with constitutive Shh pathway
activation, medulloblastoma tumorigenesis shows several
stages of progression, with clusters of preneoplastic
GNPs (pGNPs) that actively express Shh target genes
such as cyclin D1 remaining on the surface of the mature
cerebellum. These cells can be considered a preneoplastic
intermediate, some of which develop into larger lesions
and then tumors [55-58]. In SmoA1 transgenic mice,
the tumorigenic effect of SmoA1 is balanced by tumor
suppressive mechanisms, such that while all mice develop
pGNPs, not all develop tumors. Control of proliferation,
differentiation, and apoptosis all limit the growth of
pGNPs [58, 59]. During the latent period that precedes
tumor detection in multiple medulloblastoma mouse
models, pGNPs acquire additional oncogenic changes
that mediate progression from the precursor state to a fully
tumorigenic state. Therefore, we assessed whether Gmnn
deficiency could alter pGNP proliferation, differentiation,
or survival during the postnatal period.
To assess whether Gmnn deficiency modified the
growth or survival of preneoplastic GNPs, we initially
analyzed early hyperplastic lesions in the SmoA1
medulloblastoma model. During normal development,
the P14-P16 EGL is comprised of 2-3 GNP cell layers,
as most GNPs have completed their migration into the
IGL (for example, in Nes-Cre; Gmnn+/fl animals lacking
the SmoA1 transgene, Figure 3A). At this time, mice with
a single copy of the SmoA1 transgene have thickened
EGL regions, expanded as nodular formations within the
cerebellar lobules. At P14, heterozygous mice that retained
Gmnn activity (SmoA1; Nes-Cre; Gmnn+/fl) displayed
thicker EGL regions than animals homozygous for the
Gmnn floxed allele (SmoA1; Nes-Cre; Gmnnfl/fl) (Figure
www.impactjournals.com/Genes&Cancer

Geminin deficiency reduces the persistence of
preneoplastic granule neuron precursor cells in
the SmoA1 model by activation of a DNA damage
response and apoptosis
In our work above, we demonstrated that NesCre-driven Gmnn deficiency enhanced survival in the
SmoA1 medulloblastoma mouse model. Likewise, at
P28, SmoA1; Nes-Cre; Gmnnfl/fl cerebella exhibited
significantly fewer pGNPs than were seen in cerebella of
SmoA1; Nes-Cre; Gmnn+/fl animals. These data suggested
that Gmnn deficiency compromised the persistence of
pGNPs, which could account for decreased rates of
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tumor formation in these animals. This reduction in
numbers of persisting pGNPs could result from enhanced
differentiation, diminished proliferation, or altered
survival of pGNPs.
To address which of these mechanisms could
contribute to the reduced numbers of pGNPs observed
in the SmoA1; Nes-Cre; Gmnnfl/fl animals, we
immunostained cerebella from P14 SmoA1; Nes-Cre;
Gmnn+/fl and SmoA1; Nes-Cre; Gmnnfl/fl littermates
with antibodies against γH2AX (induction of DNA
damage response), cleaved (active) Caspase-3 (apoptotic
marker), phosphorylated histone H3 (pH3; mitotic cell
marker), p27kip1 (cell cycle exit accompanying GNP
differentiation), and CyclinD1 (proliferative cell marker).
We observed a significant increase in the fraction of
pGNPs expressing both γH2AX (Figure 4A, 4C) and
active Caspase-3 (Figure 4B, 4D) in SmoA1; Nes-Cre;
Gmnnfl/fl cerebella, by comparison with littermates that
retained Gmnn activity (SmoA1; Nes-Cre; Gmnn+/fl).
This result suggests that Gmnn loss results in increased
accumulation of DNA damage and apoptotic cell death of
pGNPs. An adjacent matched section for each genotype
was also stained with hematoxylin and eosin, confirming
the differences in overall thickness of the EGL in the
sections examined (Figure 4E). By contrast, there did
not appear to be significant differences in the fraction of
pGNPs that were immunopositive for Cyclin D1, p27kip1,
or pH3 in the SmoA1; Nes-Cre; Gmnn+/fl versus SmoA1;
Nes-Cre; Gmnnfl/fl backgrounds (Supplementary Figure
7), suggesting that Gmnn deficient pGNPs could still
proliferate and undergo cell cycle exit and differentiation.
These results suggest that Gmnn loss sensitizes pGNPs to
accumulation of DNA damage and apoptosis, which could
account for the reduced numbers of persisting pGNPs
and the enhanced survival observed in SmoA1; Nes-Cre;
Gmnnfl/fl animals.

(Figure 5A-5B). Acute Gmnn knockdown with both
siRNAs significantly impaired Daoy cell growth in vitro,
resulting in a plateau and subsequent decline in cell
numbers (Figure 5C).
We conducted cell cycle analysis in Daoy cells
72 hours after Gmnn or control (GAPDH) siRNA
knockdown, without prior synchronization of the cell
population. Gmnn knockdown resulted in a significant
accumulation of cells with 4N DNA content, e.g. in the
G2/M phases of the cell cycle (Figure 5D-5E). To better
quantify the increased numbers of 4N (G2/M phase)
cells following Gmnn knockdown, we synchronized
the cell population in G1/S by hydroxyurea treatment
(treatment conditions defined in Supplementary Figure
9). Gmnn knockdown likewise induced accumulation of
these synchronized Daoy cells in G2/M, with pronounced
effects seen in synchronized cell populations 48 hrs. after
hydroxyurea release, corresponding to 72 hrs. of Gmnn
knockdown (Figure 5F-5G). We next assessed whether
Gmnn knockdown caused Daoy cells to arrest in the G2
or M phase of cell cycle, by combining FACS for a mitotic
marker (phosphorylated histone H3; pH3) with propidium
iodide analysis for cellular DNA content. No reproducible
differences in numbers of M-phase cells were detected
in the Gmnn siRNA condition, by comparison with the
GAPDH siRNA control (Figure 6). These results suggest
that Gmnn knockdown causes significant accumulation of
cells in the G2 phase rather than M phase of the cell cycle.

Geminin depletion induces activation of G2
checkpoint and DNA damage response pathways
and apoptosis in human medulloblastoma cells
Gmnn deficient Daoy cells accumulated in the
G2 phase of the cell cycle. This could potentially occur
subsequent to DNA damage incurred during S phase,
such as DNA re-replication by unimpeded Cdt1 activity,
and the resulting replication stress would be expected to
activate DNA damage checkpoint pathways. Therefore, to
assess checkpoint pathway activation, we compared levels
of phosphorylated, activated Chk1 and Chk2 checkpoint
kinases in control versus Gmnn knockdown Daoy cells.
Both Gmnn siRNAs strongly induced activation of Chk1,
while the more effective knockdown construct (siGmnn#6)
also induced strong activation of Chk2 (Figure 7A-7D).
As recruitment of γH2AX to chromatin is an early
indicator of activation of DNA damage repair processes,
we performed immunostaining for γH2AX to test whether
Gmnn deficiency triggered a DNA damage response.
Etoposide treated Daoy cells were used as a positive
control for DNA damage and these cells stained positive
for γH2AX (Figure 7E). While γH2AX immunopositive
cells were not seen in control siRNA transfected cells,
Gmnn depletion with both siRNAs resulted in formation
of γH2AX -positive foci in >75-80% of cells (Figure 7E,

Geminin knockdown induces cell cycle arrest of
human medulloblastoma cells
SmoA1 pGNPs and tumor cells from the mouse
model are not amenable to long-term culture ex vivo (data
not shown). Therefore, to further assess whether Gmnn
deficiency could affect medulloblastoma cell proliferation,
growth, and/or survival, we also manipulated Gmnn levels
in Daoy cells, a widely used human medulloblastoma
cell line that mimics some characteristics of the Shh
medulloblastoma subtype [60-62]. We performed a dose
response curve to identify the lowest concentration of
small interfering RNAs (siRNAs) that significantly
reduced Gmnn levels in Daoy cells (Supplementary Figure
8). We validated two independent siRNAs directed against
human Gmnn, each of which induced 85-90% reduction
in Gmnn protein levels, with siGmnn#6 consistently
reducing Gmnn levels even more strongly than siGmnn#2
www.impactjournals.com/Genes&Cancer
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Figure 4: Geminin loss increases pGNPs expressing markers of the DNA damage response and apoptosis.

Immunohistochemistry for γH2AX and cleaved (active) Caspase3 on P14 cerebellar sections from animals hemizygous for the Nes-Cre and
SmoA1 transgenes and either heterozygous or homozygous for the Gmnn floxed allele. Matched representative sections are shown for each
genotype in (A-B), with matched hematoxylin-eosin stained sections in E. (C-D) Immunopositive pGNPs were quantified and represented
as average counts/section with *<0.05 defined by two-tailed student’s t-test.
www.impactjournals.com/Genes&Cancer
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Interference with Geminin activity acts
synergistically with the topoisomerase inhibitor
etoposide

7G). As failure to repair DNA damage may trigger cell
death by apoptosis, we also assessed the status of cleaved
Caspase-3, a marker for apoptosis, in control and Gmnn
knockdown cells. By comparison with control cells,
knockdown of Gmnn significantly increased levels of
cleaved Caspase-3, as assessed by both immunostaining
and Western blotting analyses (Figure 7F, 7H-7I).

Standard treatment for medulloblastoma includes
maximal safe tumor resection, followed by craniospinal
irradiation and multi-agent chemotherapy [39]. The
topoisomerase inhibitor etoposide (VP-16) has been

Figure 5: Geminin knockdown causes DNA re-replication and G2/M cell cycle arrest in human medulloblastoma
cells. (A). Gmnn siRNA knockdown in Daoy cells was performed using 25 nM of Gmnn siRNAs #2 or #6 (see Methods) and levels
of knockdown were assessed after 72hrs by Western blotting (A) and by qRTPCR (B), revealing ~90% knockdown achieved with each
siRNA. (C) Growth curve: 6X105 cells were seeded and siRNA transfection was performed 24 hrs later (time 0). Numbers of cells were
counted 24, 48, and 72 hr. post-transfection. (D-E) 72 hrs. after Gmnn siRNA knockdown, cells were stained with propidium iodide and
1X106 cells for each condition were analyzed for DNA content using FACS. Representative FACS plots are shown in D. In E, the fraction
of cells with 4N DNA content following Gmnn siRNA knockdown is represented as a fold ratio relative to the GAPDH siRNA control.
An average value obtained from four independent biological replicates is shown. (F-G) Daoy cells were synchronized with hydroxyurea
as described (Methods) and effectiveness of synchronization (arrest of cells in G1/S) is shown in Figure S9. Percentages of cells in G2/M
were determined by FACS analysis and quantified as described in D-E, for 3 independent biological replicates. p-values: *<0.05, **<0.01,
***<0.001 were defined by two-tailed student’s t-test.
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used as a component of combinatorial chemotherapy for
newly diagnosed and recurrent medulloblastoma [63-65].
Interestingly, in addition to interacting with Cdt1, Gmnn
can interact with Topoisomerase IIα (Topo IIα), a target
for etoposide, which resolves chromosomal catenanes
formed during DNA replication [12, 66]. Gmnn was
reported to both promote recruitment of Topo IIα to
chromatin during replication and to stimulate its release
from chromosomes. Accordingly, in some cell contexts,
Gmnn over-expression triggers premature Topo IIα release
from chromosomes, increasing cellular resistance to the
Topo IIα poisons etoposide and doxorubicin, which act
by trapping the chromosomally bound transient reaction
intermediate [12, 66].
Since Gmnn can interact with Topo IIα, and
Topo IIα inhibitors like etoposide are used to treat
medulloblastoma, we additionally investigated whether
Gmnn inhibition could potentiate etoposide efficacy.
We began by performing a dose-response for etoposide
treatment of Daoy cells, to identify a dose that caused a
modest accumulation of cells in the G2 phase (Figure 8A).
We used this dose (100nM) of etoposide in combination
with control or Gmnn knockdown and found that Gmnn
inhibition using either siRNA acts additively with
etoposide to increase the G2 accumulation of Daoy
cells (Figure 8B-8C). Taken together, these data suggest
that inhibition of Gmnn can induce cell cycle arrest,
DNA damage checkpoint activation, and apoptosis of
medulloblastoma cells, and could potentially sensitize
tumor cells to combination chemotherapies involving
etoposide.

function. Therefore, to determine whether Gmnn inhibition
represented a plausible approach for selective targeting of
cancer cells in medulloblastoma, we thoroughly examined
effects of Gmnn loss on neurological function in the
Nes-Cre conditional knockout model. Using a range of
behavioral assays, we assessed age-matched male and
female cohorts of adults carrying one copy of the NesCre transgene that were either wild-type for Gmnn or
homozygous for the floxed Gmnn allele. We first assessed
possible impairment of learning and memory and simple
motor and sensorimotor functions, which might confound
performance in cognitive tests. This involved quantifying
performance during a one hour locomotor activity and
exploratory behavior test, a battery of sensorimotor
measures, and the Morris water navigation task. We also
conducted a series of additional tests at a slightly older age
to evaluate other behavioral parameters. These included
the elevated plus maze, acoustic startle/pre-pulse inhibition
of startle, hole board exploration/olfactory preference,
and social approach, in that order. None of these tests
revealed a distinct behavioral phenotype resulting from
Nes-Cre-mediated conditional loss of Gmnn function
(Supplementary Figure 10 and Supplemental Results
and Methods). Our behavioral testing efforts do not
qualify as a definitive evaluation of all possible untoward
effects of conditional loss of Gmnn function. However,
our data suggest that therapeutic interventions involving
targeting of Gmnn activity in the developing nervous
system are unlikely to have major deleterious effects on
neurodevelopment or neurological function.

DISCUSSION

Nestin-Cre-mediated Geminin excision in the
nervous system does not alter motor, cognitive, or
other behavioral functions

Geminin deficiency suppresses medulloblastoma
tumorigenesis

Since medulloblastoma develops during childhood,
selective therapies should target cancer cells without
affecting normal neurodevelopment or neurological

The Shh-driven subtype accounts for about 30%
of all medulloblastomas [44, 67], with GNPs serving as

Figure 6: Geminin knockdown results in cell cycle arrest in G2 rather than M phase. Representative FACS plots of cells
analyzed for DNA content (PI: x-axis) and by immunocytochemistry for pH3 (y-axis). Similar percentages of highly pH3 immunopositive
cells (M-phase cells) were seen in all three knockdown conditions.
www.impactjournals.com/Genes&Cancer
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the cell of origin [68, 69]. During cerebellar development
in the mouse, GNP proliferation in the EGL is maximal
at about one week after birth, while by three weeks the
GNPs have differentiated and migrated into the IGL.
In the SmoA1 model at P14-P16, the EGL remains
thickened with clusters of GNPs with preneoplastic
potential remaining at the cerebellar surface. However,
Gmnn deficiency partially suppressed these effects. These
effects were also seen at four postnatal weeks, when Gmnn
loss reduced the persistence of pGNPs at the cerebellar

surface by six-fold in the SmoA1 model. These findings
correspond with altered frequencies of tumorigenesis in
cohorts of SmoA1 transgenic animals with versus without
Gmnn loss, with Gmnn loss conferring a significant
survival advantage. These data suggest that Gmnn
deficiency may modify pGNP tumorigenic potential from
an early developmental timepoint, diminishing pGNP
persistence at the cerebellar surface and reducing the rate
at which medulloblastoma tumors form under conditions
of constitutively active Shh signaling.

Figure 7: Geminin depletion induces G2 checkpoint activation, DNA damage response, and apoptosis in human
medulloblastoma cells. (A-B) siRNA knockdown was performed on unsynchronized Daoy cells as above. Representative westerns

for phosphorylated-Chk1 and Chk2 are shown relative to total Chk1/2 and to the γTubulin loading control. (C-D) Quantitation of changes
in phosphorylated Chk1/2 was performed by quantification of band intensity and is represented as the average of two experiments. (E-F)
Immunocytochemistry for γH2AX and activated Caspase-3 was performed on siRNA transfected cells. Representative images are shown,
with etoposide used as a positive control to induce DNA damage in E. Scale bars=50µm. (G-H) Quantification of data from E-F was
obtained by scoring >250 cells per sample type per experiment for three independent experiments. (I) Western blotting for cleaved caspase
was assessed in the siRNA transfected cells. p-values: *<0.05, **<0.01, ***<0.001 were defined by two-tailed student’s t-test. ns=not
significant.
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Figure 8: Interference with Geminin activity acts synergistically with the topoisomerase inhibitor etoposide. (A)

Etoposide dose response curve was generated by treating Daoy cells with increasing concentrations of etoposide and evaluation of DNA
content by propidium iodide staining and FACS analysis. 100 nM was selected as a dose for assessing interactions with Gmnn knockdown
in subsequent experiments. (B-C) PI FACS analysis as described previously was performed on Gmnn siRNA knockdown cells with addition
of DMSO vehicle or 100 nM etoposide. (B) Quantification of three independent experiments. Ratio of G2/M (4N) cells in etoposide,
compared with the DMSO control, is shown for each knockdown condition. (C) One representative experiment (of three independent
experiments) is shown. p-values: *<0.05, **<0.01 were defined by two-tailed student’s t-test.
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As modulating pathways that affect pGNP
proliferation, differentiation, or survival can all affect the
frequency of tumor formation [49, 70], we assessed which
processes were affected by Gmnn deficiency in the SmoA1
model. We found no significant difference in the fraction
of pGNPs expressing cyclin D1, the mitotic marker pH3,
or p27Kip1 in cerebella of SmoA1 retaining versus with loss
of Gmnn expression. These data suggest that loss of Gmnn
did not grossly alter the ability of pGNPs to proliferate,
exit the cell cycle, or differentiate. By contrast, Gmnn
loss in the SmoA1 model significantly increased relative
numbers of pGNPs immunopositive for γH2AX , which
marks cells with DNA damage, and cleaved Caspase-3,
which labels cells undergoing apoptosis. These data
suggest that Gmnn deficiency can trigger a DNA damage
response in pGNPs in the SmoA1 model from early stages,
elevating rates of pGNP apoptosis. This may account for
the reduced numbers of pGNPs persisting at the cerebellar
surface at later postnatal stages and for the survival
advantage later observed in these animals.

re-firing of origins of replication within the same cell cycle
[11]. Gmnn expression is elevated in many tumor cells,
and may constrain this additional pre-RC complex activity,
such that altering this balance by Gmnn depletion would
preferentially trigger DNA damage due to re-replication
and checkpoint arrest in cancer cells. Interestingly, here
we found that Gmnn levels in human medulloblastomas
did not correlate with tumor subtype, histology, or other
criteria, but did correlate with elevation of cell cycle
related genes, including pre-RC proteins (MCM6, ORC1,
and ORC6). This would be compatible with a need for
elevated Gmnn to balance increased pre-RC expression,
to maintain genome integrity and facilitate tumor growth.
Gmnn inhibition elicits distinct, cell type-specific
responses. In some cells, Gmnn inhibition results in
extensive genome re-replication, with G2 checkpoint
arrest triggered by production of aneuploid cells with >4N
DNA content. However, other cell types (for example,
immortalized human mammary epithelial cells) undergo
mitotic rather than G2 arrest upon Gmnn silencing [66,
71]. In these cells, Gmnn loss does not cause S phase
progression defects or genome over-replication, but rather
causes mitotic arrest, inability to exit mitosis, and the
formation of unresolved chromosomal bridges. We found
that inhibition of Gmnn in human Daoy medulloblastoma
tumor cells caused accumulation of cells in G2 without
significant changes in numbers of M-phase cells.
However, unlike the cancer cell lines characterized by Zhu
et al., in which 28-44% of cells exhibited extensive DNA
re-replication [10], Gmnn depletion in Daoy cells resulted
in a much more modest fraction of >4N cells. However,
70-80% of these cells accumulated γH2AX-positive
DNA damage foci and underwent spontaneous apoptosis,
measured by cleaved Caspase-3 immunopositivity.
Blow and colleagues have suggested that levels
of re-replication resulting from Gmnn depletion may be
influenced by the length of G2 arrest, with prolonged G2
checkpoint arrest enabling Cdt1 accumulation, which
promotes additional genome re-replication and greater
DNA damage [72]. This may constitute a protective
response, making re-replication into an all-or-nothing
phenomenon to prevent accumulation of cells with low
levels of re-replication [72]. Modest induction of rereplication subsequent to either Gmnn deficiency or Cdt1
overexpression is sufficient to induce G2 checkpoint
activation [72, 73]. Inappropriate re-licensing can also
result in other forms of DNA damage, including headto-tail replication fork collision and the tendency of
re-replicating forks to collapse [74, 75]. Therefore,
even minor induction of re-replication or other types of
replication stress (for example, those related to altered
Topo IIα decatenation activity) could also damage the
genome in S phase in a manner that may not be apparent
as a significant fraction of G2/M cells with >4N DNA
content. The ability of minor amounts of replication
stress to trigger a DNA damage response and subsequent

Geminin is required to maintain the fidelity of
DNA replication in medulloblastoma
The pre-RC protein Cdt1 is essential for loading
DNA helicases onto origins of DNA replication. Cdt1
inactivation prevents genome re-replication within a cell
cycle and occurs through multiple mechanisms [4-9].
During S-phase, cyclinA:CDK2 complexes phosphorylate
Cdt1, targeting it for SCFSkp2–dependent ubiquitination,
while CDRDdb1 also ubiquitinates Cdt1, both of which
promote Cdt1 proteolysis. Gmnn’s ability to specifically
bind to Cdt1 during S/G2 phases of the cell cycle
constitutes a third system for controlling Cdt1 activity,
both preventing Cdt1 from reinitiating DNA replication
and also protecting Cdt1 from proteolytic degradation [1,
2, 4, 7, 9].
Since Gmnn inhibits Cdt1, Gmnn depletion
can result in genome re-replication within a cell cycle,
through increased Cdt1 activity. However, prior work
had suggested that cells derived from normal tissues
and cancer cells may exhibit differential dependence
upon Gmnn to prevent DNA re-replication [10]. In Zhu
et al., siRNA knockdown of Gmnn caused re-replication
and triggered apoptosis in a wide variety of cancer cell
lines, while inducing similar effects in non-cancer cell
lines required combined suppression of Gmnn and
Cyclin A [10]. These data suggest that Gmnn may be
the primary regulator of Cdt1 inhibition in cancer cells,
while additional safeguards are sufficient to constrain
DNA re-replication to maintain genome fidelity in many
non-cancer cell contexts. Preferential sensitivity of
some cancer cells to Gmnn depletion may involve their
overexpression of pre-RC proteins including Cdt1 and
Cdc6, which stimulate pre-RC complex re-assembly and
www.impactjournals.com/Genes&Cancer
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apoptosis could account for the results seen here in vivo.
In the SmoA1 model, Gmnn deficiency strongly induced
γH2AX and cleaved Caspase-3 immunopositivity in
pGNPs. By P28, these Gmnn deficient animals had
six-fold fewer pGNPs at the cerebellar surface, likely
contributing to the enhanced survival of the Gmnndeficient cohort. However, the SmoA1 tumors that did
form in Gmnn-deficient animals had similar fractions
of proliferative cells as those without Gmnn deficiency,
while the fraction of pGNPs expressing proliferative cell
markers was not grossly altered by Gmnn deficiency.
These findings suggest that Gmnn-deficient preneoplastic
and cancer cells may be sensitized, potentially by
incurring DNA damage, to undergo apoptosis even under
conditions where they do not exhibit cell cycle arrest or
grossly altered proliferative capacity.
Both in mouse in vivo and human in vitro models
of medulloblastoma, Gmnn deficiency triggered a
DNA damage response and apoptosis. In human
medulloblastoma cells, the DNA damage response was
accompanied by activation of both ATR/Chk1, which is
activated in response to DNA damage other than double
strand breaks, including replication stress, and ATM/Chk2,
which is activated predominantly in response to double
strand breaks [76, 77]. Interestingly, Gmnn knockdown
using the two siRNAs yielded slightly different results,
with siGmnn-2 only activating pChk1 while siGmnn-6
activated both pChk1 and pChk2. The siGmnn-6 construct
yields higher knockdown of Gmnn compared to siGmnn-2,
suggesting that the extent of Gmnn loss may affect the
nature and extent of DNA damage that occurs upon Gmnn
knockdown in medulloblastoma cells, with the siGmnn-2
construct predominantly triggering replication stress
leading to ATR/Chk1 activation, while more effective
knockdown with siGmnn-6 resulted both in higher levels
of replicative stress and induction of double strand DNA
breaks, activating both pChk1 and pChk2.
In some cancer cell contexts, effects of Gmnn
inhibition have been shown to be independent of the
mutational status of the tumor suppressor TP53, with
Gmnn loss inducing accumulation of excess genomic
DNA, G2/M checkpoint activation, and apoptosis in both
TP53+ and TP53- cells [10, 78, 79]. We focused our in
vitro studies here on the Daoy human medulloblastoma
cell line. Daoy cells are the oldest established
medulloblastoma cell line: they were first isolated in
1985 from a 4-year old boy [60] and have been utilized
in more studies than any other medulloblastoma cell line
[61], with molecular subtyping indicating that they mimic
the SHH pathway activated subtype of medulloblastoma
[62]. The Daoy cell line harbors a single point mutation of
the tumor suppressor TP53, resulting in a substitution of
phenylalanine for a cysteine at amino acid 242 and loss of
functional p53 [80, 81]. By contrast, the SmoA1 mouse
model used here has intact TP53 activity. TP53 mutations
are only found in a fraction of human medulloblastomas
www.impactjournals.com/Genes&Cancer

of the Wnt (16%) and Shh (21%) subtypes, although
they correlate with poor survival and treatment failures
in Shh-driven medulloblastoma [38, 82, 83]. However, in
both of our experimental models, loss of Gmnn resulted
in a similar induction of the DNA damage response
and apoptosis. This suggests that, as in other cancer
cell contexts, Gmnn inhibition can elicit some effects
regardless of TP53 status, such that Gmnn-directed
therapeutics could potentially have similar efficacy in both
TP53+ and TP53- forms of medulloblastoma.

Geminin deficiency sensitizes medulloblastoma
cells to etoposide treatment
Another mechanism by which Gmnn levels could
influence genome integrity is through interactions with
Topo IIα, which removes catenated intertwines between
sister chromatids to separate replicated chromosomes.
Gmnn-Topo IIα interaction may facilitate Topo IIα
activity during termination of DNA replication [66]. In
human mammary epithelial (HME) cells, physiologically
normal Gmnn levels are needed to both facilitate Topo
IIα recruitment to chromosomes, by promoting Topo IIα
phosphorylation, and for recruitment of deSUMOylating
enzymes to Topo IIα, to promote its release from
chromatin. In that work, Gmnn over-expression promoted
premature Topo IIα release from chromatin and increased
the resistance of HME and breast cancer cells to Topo
IIα inhibitors such as etoposide, which trap the transient
Topo IIα reaction intermediate on chromatin to prevent
DNA religation and promote cell death. These findings
suggested that the high levels of Gmnn expression we
observed in medulloblastoma could contribute to etoposide
resistance, while inhibiting Gem might chemosensitize
cells in multi-agent chemotherapy treatments involving
etoposide. We found that Gmnn inhibition indeed
enhanced the responsiveness of medulloblastoma cells to
etoposide treatment, significantly increasing the fraction
of cells that underwent G2 checkpoint arrest. Therefore,
given the utilization of etoposidase and other Topo IIα
inhibitors in current medulloblastoma chemotherapies,
inhibition of Gmnn in this context might have the potential
to enhance efficacy and/or re-sensitize resistant cells.
We performed these experiments in the Daoy cell line,
because it is amenable to in vitro culture, while we could
not culture tumor cells from the SmoA1 mouse model
ex vivo. However, the Daoy model has limitations as a
model of medulloblastoma: it is hypertetraploid, with
a modal chromosome number of 93-99, and carries a
TP53 mutation, while most human medulloblastomas
do not exhibit these features [60, 61, 80, 81]. Therefore,
in future studies, it would be of interest to test whether
Gmnn loss or inhibition could also enhance the efficacy
of etoposide treatment in the context of in vivo models of
medulloblastoma.
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Since medulloblastoma is a childhood cancer that
occurs during development and maturation of the nervous
system, we also assessed whether Gmnn inhibition could
be used to selectively target cancer cells without affecting
nervous system development or neurological function.
Prior work describing neurodevelopmental phenotypes
of Nes-Cre-mediated Gmnn loss has yielded conflicting
results. Schultz et al. described these animals as having
normal neural stem cell function and normal neurogenesis
[52], while Spella et al. suggested that Nes-Cre-driven
Gmnn loss led to expansion of neural progenitors during
ex vivo cortical progenitor culture [84]. One experimental
variable that may underlie these conflicting findings is
use of different Nes-Cre transgenic lines with distinct
sites of integration, which may influence transgene
expression. Our work here used (Nes-cre)1Kln, which
was previously documented to result in significantly
diminished Gmnn protein in CNS tissues by E14.5 [52].
Using this Nes-Cre driver, Gmnn loss did not result in
detectable alterations of neurological function, which was
assessed by conducting an extensive panel of behavioral
and motor assays. Therefore, these data suggest that Gmnn
requirements for neural development are restricted to early
embryogenesis and support the potential utility of Gmnn
directed therapeutics in selective targeting of cancer cells
in medulloblastoma.
Efforts are underway to define small molecules that
induce cancer-selective induction of re-replication, cell
cycle arrest, and spontaneous apoptosis, by inhibiting
the activity of Gmnn or of other molecular controls that
prevent excessive DNA replication [12, 78]. Our work
here demonstrates that, while Gmnn appears largely
dispensable for normal neurodevelopment and normal
neurological function after early embryogenesis, Gmnn
inhibition can impair the growth of both preneoplastic
and tumor cells in medulloblastoma, inducing them to
undergo a DNA damage response and apoptosis. These
effects were observed both in a mouse in vivo model of
medulloblastoma and in human medulloblastoma cells,
and resulted in increased survival in the mouse model,
while Gmnn deficient medulloblastoma cells were
also sensitized to treatment with the Topo IIα inhibitor
etoposide. As anticancer agents targeting Gmnn become
available, our work here suggests they may have utility in
combination chemotherapies targeting medulloblastoma.

Data platform is u133p2 [HG-U133_Plus_2] Affymetrix
Human Genome U133 Plus 2.0 Array, MAS5.0 with
normalization applied by R2) 2log expression data was
compared for normal cerebellum (sample accession: Roth;
n=9; GSE3526) versus four sets of medulloblastoma
samples (Gilbertson, n=76, GSE37418; Pfister; n=73,
GSE49243; Delattre, n=57; Kool, n=62, GSE10327).

Mouse strains and animal husbandry
Animal studies were conducted under protocols
approved by the Washington University Institutional
Animal Care and Use Committee. Gmnn conditional
knockout mice (CSD24729) were purchased from
the Knockout Mouse Project (KOMP). This targeted
Gmnn allele contains a splice acceptor-βgeo-polyA
sequence flanked by FRT sites (permitting excision
by FLPe recombinase) inserted into intron 3 and loxP
sites flanking exon 4 (permitting excision of exon 4 by
Cre recombinase). Prior to FLPe excision of the splice
acceptor-βgeo-polyA sequence, the targeted allele is
predicted to be a null allele of Gmnn. Excision by FLPe
recombinase results in a targeted (floxed) allele that
generates a wild-type mRNA. This floxed allele can be
converted to a null allele in the presence of Cre, which
excises exon 4. C57BL/6-Tg(Neurod2-Smo*A1)199Jols/J
(Jax 008831) and B6.Cg-Tg(Nes-Cre)1Kln/J (Jax 003771)
mice were obtained from Jackson laboratories.

Brain isolation, sectioning and immunohistochemistry
Mice were euthanized by cardiac perfusion
after anaesthesia according to institutionally approved
protocols. Brains were processed overnight in 4%
paraformaldehyde and embedded in paraffin, and matched
5 µm para-sagittal sections for each genotype were
processed for immunohistochemistry (IHC) or stained
with hematoxylin and eosin. IHC was as previously
described [29] using the primary antibodies indicated, and
slides were processed for Streptavidin-Peroxide detection
using the Invitrogen Histostain-SP kit Cat No. #95-9943
LAB-SA detection system, following the manufacturer’s
protocol.

MATERIALS AND METHODS

Immunocytochemistry
Human tumor expression

Cells were fixed using 4% paraformaldehyde,
washed with PBS containing 0.1% TritonX-100, blocked
with PBS containing 1% donkey serum, 1% BSA and
0.1% TritonX-100, and incubated with the respective

Comparison of Gmnn expression in normal
cerebellum versus in medulloblastoma tumors used the
R2: MegaSampler (hgserver1.amc.nl/cgi-bin/r2/main.cgi).
www.impactjournals.com/Genes&Cancer
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primary antibodies overnight at 4°C. The next day, the
slides were washed as above, and secondary antibody
staining was performed along with DAPI staining. The
slides were mounted using Prolong Gold anti-fade (Life
Technologies: P36931) and imaged using a confocal
microscope, with all images taken at 20X magnification.

AACUUCCAGCCCUGGGGUUAUUU [10], siGem-6:
Target
sequence
GAAUAGUUCUGUCCCAAGA
(siGENOME Human Gmnn Dharmacon), siGAPDH:
UGGUUUACAUGUUCCAAUA (siGENOME Gapdh
control Dharmacon).

Growth curve analysis

Antibodies

Cells were counted and seeded at 600,000 cells/
ml on Day 0 and transfected 24 hours later following the
methods described in the earlier section. The cell numbers
in each condition were counted and plotted on the growth
curve.

Primary
antibodies
used
for
IHC,
Immunocytochemistry, or Western blotting were
Gmnn: sc-13015 (Santa Cruz), Ki67: MA1-90584
(ThermoFisher), Cleaved Caspase-3: #9661 (Cell
Signaling), Cyclin D1: #134175 (Abcam), p27Kip1:
#32034 (Abcam), Phospho-histone H3: 06-570
(Millipore), γH2AX : 05-636 (Millipore); total CHK2:
#2662 (Cell Signaling Technology); Phospho-(T68)
CHK2: BS4043 (Bioworld); Phospho-CHK1: #2341
(Cell Signaling Technology); Total CHK1: #2360 (Cell
Signaling Technology); γTubulin: ab16504 (Abcam),
GAPDH: G9545 (Sigma Aldrich).

FACS analysis
1 million cells from each condition were pelleted,
washed with PBS (without calcium and magnesium), resuspended in FACS buffer (PBS plus 3% FBS, 0.04%
Na-Azide and 1mM EDTA), and fixed by adding drops
of ice cold 70% ethanol. The cells were stained with 1mg/
ml propidium iodide (P4864; Sigma; 400µl) in 10 mls of
PBS plus RNase A (500µl). Single cell suspensions of 1
million cells per condition were used for FACS analysis,
with propidium iodide staining as a measure for DNA
content and cell cycle analysis was performed using FloJo
software.

qRTPCR and immunoblotting
Total RNA was extracted with the Clontech
Nucleospin RNA extraction kit (#740955.250), using
the manufacturer’s protocol. cDNA was synthesized
using the Bio Rad iScript Reverse Transcriptase
Supermix (#170-8841), followed by quantitative
RT-PCR analysis using the Fast SYBR green mix
from Applied Biosystems (#4385612), as previously
described [34]. Primers used were: mouse Gmnn
(F- GCAGTACATGGCGGAGGTAATC and RGCTCCTGAGTCTTCCAGTTCTG), mouse α-Actin
(FCATTGCTGACAGGATGCAGAAGG
and
R- TGCTGGAAGGTGGACAGTGAGG),
human
Gmnn (F- CAGCCTTCTGCATCTGGATCTC and
RCCAGGGCTGGAAGTTGTAGATG),
human
GAPDH
(FGTCTCCTCTGACTTCAACAGCG
and R- ACCACCCTGTTGCTGTAGCCAA), human
α-Actin (F- CACCATTGGCAATGAGCGGTTC and
R- AGGTCTTTGCGGATGTCCACGT). Protein lysate
preparation and Western blotting was performed as
previously described [30].

Cell cycle synchronization with Hydroxyurea
Daoy cells were counted and seeded at 600,000
cells/10 cm dish. 24 hours later cells were transfected
with siRNAs targeting Gmnn (siGem-2 and siGem-6)
or Gapdh as a control, using Lipofectamine RNAi max
transfection protocol (Thermo Fisher). 25 nM of each
siRNA was used. 12 hours later the cells were treated with
2 mM hydroxyurea (Sigma Aldrich H8627), to arrest the
cells in the G1 phase of cell cycle, after [85]. After 14 hrs.
of hydroxyurea treatment, cells were thoroughly washed
with DMEM +10% FBS medium to remove any residual
hydroxyurea, and were pelleted for propidium iodide
staining and FACS analysis 48 hours after the HU release.
Etoposide treatment. 100nM final etoposide (E1383;
Sigma Aldrich) dose was used in treating Daoy cells in
comparison with a DMSO only treatment control. For
ICC, positive control cells for γH2AX staining were
generated by treating Daoy cells with 1 µM etoposide for
24 hours.

Cell culture and siRNA transfection
The Daoy (ATCC HTB-186) cell line was grown
in 10% FBS containing DMEM medium. Lipofectamine
RNAi max reagent from Thermo Fisher Scientific
was used for siRNA transfections following the
manufacture’s protocol. siRNA sequences are: siGem-2:
www.impactjournals.com/Genes&Cancer

740

Genes & Cancer

FUNDING

mammalian cells. J Cell Biochem. 2005; 96: 879-87. doi:
10.1002/jcb.20609.

Funding was provided by the National Institutes
of Health (GM66815), the March of Dimes (#1-FY10381) and the Association for Research of Childhood
Cancer to K.L.K. Support for the animal behavioral
studies core (D.F.W.) was provided by the Intellectual
and Developmental Disabilities Research Center at
Washington University (NICHD U54 HD087011).

12. Depamphilis ML. Spotlight on Geminin. Breast cancer
research : BCR. 2011; 13: 109.
13. Blanchard Z, Malik R, Mullins N, Maric C, Luk H, Horio
D, Hernandez B, Killeen J, Elshamy WM. Geminin
overexpression induces mammary tumors via suppressing
cytokinesis. Oncotarget. 2011; 2: 1011-27.
14. Montanari M, Boninsegna A, Faraglia B, Coco C, Giordano
A, Cittadini A, Sgambato A. Increased expression of
geminin stimulates the growth of mammary epithelial cells
and is a frequent event in human tumors. J Cell Physiol.
2005; 202: 215-22.

CONFLICTS OF INTERESTS
The authors have no conflict of interest to declare.

15. Gonzalez MA, Tachibana K-EK, Chin S-F, Callagy G,
Madine MA, Vowler SL, Pinder SE, Laskey RA, Coleman
N. Geminin predicts adverse clinical outcome in breast
cancer by reflecting cell-cycle progression. J Pathol. 2004;
204: 121-30.

REFERENCES
1.

DePamphilis ML, Blow JJ, Ghosh S, Saha T, Noguchi K,
Vassilev A. Regulating the licensing of DNA replication
origins in metazoa. Curr Opin Cell Biol. 2006; 18: 231-9.

2.

Blow JJ, Gillespie PJ. Replication licensing and cancer--a
fatal entanglement? Nat Rev Cancer. 2008; 8: 799-806.

3.

Symeonidou I-E, Taraviras S, Lygerou Z. Control over
DNA replication in time and space. FEBS Lett. 2012; 586:
2803-12.

4.

Nishitani H, Sugimoto N, Roukos V, Nakanishi Y, Saijo M,
Obuse C, Tsurimoto T, Nakayama KI, Nakayama K, Fujita
M, Lygerou Z, Nishimoto T. Two E3 ubiquitin ligases, SCFSkp2 and DDB1-Cul4, target human Cdt1 for proteolysis.
EMBO J. 2006; 25: 1126-36.

5.

Senga T, Sivaprasad U, Zhu W, Park JH, Arias EE, Walter
JC, Dutta A. PCNA is a cofactor for Cdt1 degradation by
CUL4/DDB1-mediated N-terminal ubiquitination. J Biol
Chem. 2006; 281: 6246-52.

6.

Li X, Zhao Q, Liao R, Sun P, Wu X. The SCF(Skp2)
ubiquitin ligase complex interacts with the human
replication licensing factor Cdt1 and regulates Cdt1
degradation. J Biol Chem. 2003; 278: 30854-8. doi:
10.1074/jbc.C300251200.

7.

8.

9.

16. Wohlschlegel JA, Kutok JL, Weng AP, Dutta A. Expression
of geminin as a marker of cell proliferation in normal
tissues and malignancies. Am J Pathol. 2002; 161: 267-73.
17. Yamazaki M, Fujii S, Murata Y, Hayashi R, Ochiai A. High
expression level of geminin predicts a poor clinical outcome
in salivary gland carcinomas. Histopathology. 2010; 56:
883-92.
18. Nishihara K, Shomori K, Tamura T, Fujioka S, Ogawa
T, Ito H. Immunohistochemical expression of geminin in
colorectal cancer: Implication of prognostic significance.
Oncol Rep. 2009; 21: 1189-95.
19. Liu Y, Xu F, Zhuang H, Lai K, Xie D, Luo D, Li L, Luo
X, Xu J, Zhang M, Zhang F, Li H. Clinicopathologic
significance of immunophenotypic profiles related to
germinal center and activation B-cell differentiation in
diffuse large B-cell lymphoma from Chinese patients. Hum
Pathol. 2008; 39: 875-84.
20. Salabat M, Melstrom L, Strouch M, Ding X, Milam B,
Ujiki M, Chen C, Pelling J, Rao S, Grippo P, McGarry T,
Bentrem D. Geminin is overexpressed in human pancreatic
cancer and downregulated by the bioflavanoid apigenin in
pancreatic cancer cell lines. Mol Carcinog. 2008; 47: 83544.

Sugimoto N, Tatsumi Y, Tsurumi T, Matsukage A, Kiyono
T, Nishitani H, Fujita M. Cdt1 phosphorylation by cyclin
A-dependent kinases negatively regulates its function
without affecting geminin binding. J Biol Chem. 2004; 279:
19691-7.

21. Bravou V, Nishitani H, Song SY, Taraviras S, Varakis J.
Expression of the licensing factors, Cdt1 and Geminin, in
human colon cancer. Int J Oncol. 2005; 27: 1511-8.

Arias EE, Walter JC. Replication-dependent destruction of
Cdt1 limits DNA replication to a single round per cell cycle
in Xenopus egg extracts. Genes Dev. 2005; 19: 114-26.

22. Kroll KL, Salic AN, Evans LM, Kirschner MW. Geminin, a
neuralizing molecule that demarcates the future neural plate
at the onset of gastrulation. Development. 1998; 125: 324758.

McGarry TJ, Kirschner MW. Geminin, an inhibitor of DNA
replication, is degraded during mitosis. Cell. 1998; 93:
1043-53.

10. Zhu W, Depamphilis ML. Selective killing of cancer cells
by suppression of geminin activity. Cancer Res. 2009; 69:
4870-7.

23. Luo L, Yang X, Takihara Y, Knoetgen H, Kessel M. The
cell-cycle regulator geminin inhibits Hox function through
direct and polycomb-mediated interactions. Nature. 2004;
427: 749-53.

11. McNairn AJ, Gilbert DM. Overexpression of ORC subunits
and increased ORC-chromatin association in transformed

24. Del Bene F, Tessmar-Raible K, Wittbrodt J. Direct
interaction of geminin and Six3 in eye development.

www.impactjournals.com/Genes&Cancer

741

Genes & Cancer

Nature. 2004; 427: 745-9.

medulloblastoma. Crit Rev Oncol Hematol. 2016; 105: 3551. doi: 10.1016/j.critrevonc.2016.05.012.

25. Seo S, Herr A, Lim J-W, Richardson GA, Richardson H,
Kroll KL. Geminin regulates neuronal differentiation by
antagonizing Brg1 activity. Genes Dev. 2005; 19: 1723-34.

37. Massimino M, Biassoni V, Gandola L, Garre ML, Gatta
G, Giangaspero F, Poggi G, Rutkowski S. Childhood
medulloblastoma. Crit Rev Oncol Hematol. 2016; 105: 3551. doi: 10.1016/j.critrevonc.2016.05.012.

26. Seo S, Kroll KL. Geminin’s double life: chromatin
connections that regulate transcription at the transition from
proliferation to differentiation. Cell Cycle. 2006; 5: 374-9.
doi: 10.4161/cc.5.4.2438.

38. Ramaswamy V, Remke M, Bouffet E, Bailey S, Clifford
SC, Doz F, Kool M, Dufour C, Vassal G, Milde T, Witt
O, von Hoff K, Pietsch T, et al. Risk stratification of
childhood medulloblastoma in the molecular era: the
current consensus. Acta Neuropathol. 2016; 131: 821-31.
doi: 10.1007/s00401-016-1569-6.

27. Gonzalez MA, Tachibana K-eK, Adams DJ, van der
Weyden L, Hemberger M, Coleman N, Bradley A, Laskey
RA. Geminin is essential to prevent endoreduplication and
to form pluripotent cells during mammalian development.
Genes Dev. 2006; 20: 1880-4.

39. Thompson EM, Hielscher T, Bouffet E, Remke M, Luu
B, Gururangan S, McLendon RE, Bigner DD, Lipp ES,
Perreault S, Cho YJ, Grant G, Kim SK, et al. Prognostic
value of medulloblastoma extent of resection after
accounting for molecular subgroup: a retrospective
integrated clinical and molecular analysis. Lancet Oncol.
2016; 17: 484-95. doi: 10.1016/S1470-2045(15)00581-1.

28. Caronna EA, Patterson ES, Hummert PM, Kroll KL.
Geminin restrains mesendodermal fate acquisition of
embryonic stem cells and is associated with antagonism
of Wnt signaling and enhanced polycomb-mediated
repression. Stem Cells. 2013; 31: 1477-87. doi: 10.1002/
stem.1410.

40. Jones DT, Jager N, Kool M, Zichner T, Hutter B, Sultan
M, Cho YJ, Pugh TJ, Hovestadt V, Stutz AM, Rausch T,
Warnatz HJ, Ryzhova M, et al. Dissecting the genomic
complexity underlying medulloblastoma. Nature. 2012;
488: 100-5. doi: 10.1038/nature11284.

29. Patterson ES, Waller LE, Kroll KL. Geminin loss
causes neural tube defects through disrupted progenitor
specification and neuronal differentiation. Dev Biol. 2014;
393: 44-56. doi: 10.1016/j.ydbio.2014.06.021.
30. Yellajoshyula D, Patterson ES, Elitt MS, Kroll KL. Geminin
promotes neural fate acquisition of embryonic stem cells by
maintaining chromatin in an accessible and hyperacetylated
state. Proc Natl Acad Sci U S A. 2011; 108: 3294-9.

41. Northcott PA, Shih DJ, Peacock J, Garzia L, Morrissy
AS, Zichner T, Stutz AM, Korshunov A, Reimand J,
Schumacher SE, Beroukhim R, Ellison DW, Marshall CR,
et al. Subgroup-specific structural variation across 1,000
medulloblastoma genomes. Nature. 2012; 488: 49-56. doi:
10.1038/nature11327.

31. Lim JW, Hummert P, Mills JC, Kroll KL. Geminin
cooperates with Polycomb to restrain multi-lineage
commitment in the early embryo. Development. 2011; 138:
33-44. doi: 10.1242/dev.059824.

42. Taylor MD, Northcott PA, Korshunov A, Remke M, Cho
Y-J, Clifford SC, Eberhart CG, Parsons DW, Rutkowski
S, Gajjar A, Ellison DW, Lichter P, Gilbertson RJ, et al.
Molecular subgroups of medulloblastoma: the current
consensus. Acta Neuropathol. 2012; 123: 465-72.

32. Yellajoshyula D, Lim JW, Thompson DM, Jr., Witt
JS, Patterson ES, Kroll KL. Geminin regulates the
transcriptional and epigenetic status of neuronal fatepromoting genes during mammalian neurogenesis. Mol Cell
Biol. 2012; 32: 4549-60. doi: 10.1128/MCB.00737-12.

43. Pugh TJ, Weeraratne SD, Archer TC, Pomeranz Krummel
DA, Auclair D, Bochicchio J, Carneiro MO, Carter SL,
Cibulskis K, Erlich RL, Greulich H, Lawrence MS, Lennon
NJ, et al. Medulloblastoma exome sequencing uncovers
subtype-specific somatic mutations. Nature. 2012; 488:
106-10. doi: 10.1038/nature11329.

33. Karamitros D, Patmanidi AL, Kotantaki P, Potocnik
AJ, Bahr-Ivacevic T, Benes V, Lygerou Z, Kioussis D,
Taraviras S. Geminin deletion increases the number of fetal
hematopoietic stem cells by affecting the expression of key
transcription factors. Development. 2015; 142: 70-81. doi:
10.1242/dev.109454.

44. Kool M, Korshunov A, Remke M, Jones DTW, Schlanstein
M, Northcott PA, Cho Y-J, Koster J, Schouten-van Meeteren
A, van Vuurden D, Clifford SC, Pietsch T, von Bueren
AO, et al. Molecular subgroups of medulloblastoma:
an international meta-analysis of transcriptome, genetic
aberrations, and clinical data of WNT, SHH, Group 3, and
Group 4 medulloblastomas. Acta Neuropathol. 2012; 123:
473-84.

34. Sankar S, Yellajoshyula D, Zhang B, Teets B, Rockweiler
N, Kroll KL. Gene regulatory networks in neural cell fate
acquisition from genome-wide chromatin association of
Geminin and Zic1. Sci Rep. 2016; 6: 37412. doi: 10.1038/
srep37412.
35. Patmanidi AL, Champeris Tsaniras S, Karamitros D,
Kyrousi C, Lygerou Z, Taraviras S. Concise Review:
Geminin-a Tale of Two Tails: DNA Replication and
Transcriptional/Epigenetic Regulation in Stem Cells. Stem
Cells. 2016. doi: 10.1002/stem.2529.

45. Pfister SM, Korshunov A, Kool M, Hasselblatt M, Eberhart
C, Taylor MD. Molecular diagnostics of CNS embryonal
tumors. Acta Neuropathol. 2010; 120: 553-66. doi: 10.1007/
s00401-010-0751-5.

36. Massimino M, Biassoni V, Gandola L, Garre ML, Gatta
G, Giangaspero F, Poggi G, Rutkowski S. Childhood
www.impactjournals.com/Genes&Cancer

46. Rubin JB, Rowitch DH. Medulloblastoma: a problem of
developmental biology. Cancer Cell. 2002; 2: 7-8.
742

Genes & Cancer

47. Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein
D, Lau CC, Chintagumpala M, Adesina A, Ashley DM,
Kellie SJ, Taylor MD, Curran T, Gajjar A, et al. Genomics
identifies medulloblastoma subgroups that are enriched for
specific genetic alterations. J Clin Oncol. 2006; 24: 192431.

Oncogene. 2013; 32: 2304-14. doi: 10.1038/onc.2012.248.
60. Jacobsen PF, Jenkyn DJ, Papadimitriou JM. Establishment
of a human medulloblastoma cell line and its
heterotransplantation into nude mice. J Neuropathol Exp
Neurol. 1985; 44: 472-85.
61. Ivanov DP, Coyle B, Walker DA, Grabowska AM. In vitro
models of medulloblastoma: Choosing the right tool for
the job. J Biotechnol. 2016; 236: 10-25. doi: 10.1016/j.
jbiotec.2016.07.028.

48. Wechsler-Reya RJ, Scott MP. Control of neuronal precursor
proliferation in the cerebellum by Sonic Hedgehog. Neuron.
1999; 22: 103-14.
49. Roussel MF, Hatten ME. Cerebellum development and
medulloblastoma. Curr Top Dev Biol. 2011; 94: 235-82.

62. Triscott J, Lee C, Foster C, Manoranjan B, Pambid
MR, Berns R, Fotovati A, Venugopal C, O’Halloran
K, Narendran A, Hawkins C, Ramaswamy V, Bouffet
E, et al. Personalizing the treatment of pediatric
medulloblastoma: Polo-like kinase 1 as a molecular target
in high-risk children. Cancer Res. 2013; 73: 6734-44. doi:
10.1158/0008-5472.CAN-12-4331.

50. Hatten ME. Central nervous system neuronal migration.
Annu Rev Neurosci. 1999; 22: 511-39. doi: 10.1146/
annurev.neuro.22.1.511.
51. Spella M, Britz O, Kotantaki P, Lygerou Z, Nishitani H,
Ramsay RG, Flordellis C, Guillemot F, Mantamadiotis
T, Taraviras S. Licensing regulators Geminin and Cdt1
identify progenitor cells of the mouse CNS in a specific
phase of the cell cycle. Neuroscience. 2007; 147: 373-87.

63. Cohen BH, Geyer JR, Miller DC, Curran JG, Zhou
T, Holmes E, Ingles SA, Dunkel IJ, Hilden J, Packer
RJ, Pollack IF, Gajjar A, Finlay JL, et al. Pilot Study of
Intensive Chemotherapy With Peripheral Hematopoietic
Cell Support for Children Less Than 3 Years of Age
With Malignant Brain Tumors, the CCG-99703 Phase
I/II Study. A Report From the Children’s Oncology
Group. Pediatr Neurol. 2015; 53: 31-46. doi: 10.1016/j.
pediatrneurol.2015.03.019.

52. Schultz KM, Banisadr G, Lastra RO, McGuire T, Kessler
JA, Miller RJ, McGarry TJ. Geminin-deficient neural stem
cells exhibit normal cell division and normal neurogenesis.
PLoS ONE. 2011; 6: e17736.
53. Hallahan AR, Pritchard JI, Hansen S, Benson M, Stoeck
J, Hatton BA, Russell TL, Ellenbogen RG, Bernstein ID,
Beachy PA, Olson JM. The SmoA1 mouse model reveals
that notch signaling is critical for the growth and survival
of sonic hedgehog-induced medulloblastomas. Cancer Res.
2004; 64: 7794-800.

64. Robison NJ, Campigotto F, Chi SN, Manley PE, Turner
CD, Zimmerman MA, Chordas CA, Werger AM, Allen JC,
Goldman S, Rubin JB, Isakoff MS, Pan WJ, et al. A phase
II trial of a multi-agent oral antiangiogenic (metronomic)
regimen in children with recurrent or progressive cancer.
Pediatr Blood Cancer. 2014; 61: 636-42. doi: 10.1002/
pbc.24794.

54. Lin CH, Stoeck J, Ravanpay AC, Guillemot F, Tapscott
SJ, Olson JM. Regulation of neuroD2 expression in mouse
brain. Dev Biol. 2004; 265: 234-45.

65. Tarbell NJ, Friedman H, Polkinghorn WR, Yock T,
Zhou T, Chen Z, Burger P, Barnes P, Kun L. High-risk
medulloblastoma: a pediatric oncology group randomized
trial of chemotherapy before or after radiation therapy
(POG 9031). J Clin Oncol. 2013; 31: 2936-41. doi: 10.1200/
JCO.2012.43.9984.

55. Goodrich LV, Milenkovic L, Higgins KM, Scott MP. Altered
neural cell fates and medulloblastoma in mouse patched
mutants. Science. 1997; 277: 1109-13.
56. Kim JY, Nelson AL, Algon SA, Graves O, Sturla LM,
Goumnerova LC, Rowitch DH, Segal RA, Pomeroy SL.
Medulloblastoma tumorigenesis diverges from cerebellar
granule cell differentiation in patched heterozygous mice.
Dev Biol. 2003; 263: 50-66.

66. Gardner L, Malik R, Shimizu Y, Mullins N, ElShamy
WM. Geminin overexpression prevents the completion of
topoisomerase IIalpha chromosome decatenation, leading
to aneuploidy in human mammary epithelial cells. Breast
Cancer Res. 2011; 13: R53. doi: 10.1186/bcr2884.

57. Oliver TG, Read TA, Kessler JD, Mehmeti A, Wells JF,
Huynh TT, Lin SM, Wechsler-Reya RJ. Loss of patched and
disruption of granule cell development in a pre-neoplastic
stage of medulloblastoma. Development. 2005; 132: 242539. doi: 10.1242/dev.01793.

67. Gajjar AJ, Robinson GW. Medulloblastoma-translating
discoveries from the bench to the bedside. Nature reviews
Clinical oncology. 2014; 11: 714-22. doi: 10.1038/
nrclinonc.2014.181.

58. Kessler JD, Hasegawa H, Brun SN, Emmenegger BA,
Yang ZJ, Dutton JW, Wang F, Wechsler-Reya RJ. N-myc
alters the fate of preneoplastic cells in a mouse model
of medulloblastoma. Genes Dev. 2009; 23: 157-70. doi:
10.1101/gad.1759909.

68. Schüller U, Heine VM, Mao J, Kho AT, Dillon AK, Han
Y-G, Huillard E, Sun T, Ligon AH, Qian Y, Ma Q, AlvarezBuylla A, McMahon AP, et al. Acquisition of granule neuron
precursor identity is a critical determinant of progenitor cell
competence to form Shh-induced medulloblastoma. Cancer
Cell. 2008; 14: 123-34.

59. Garcia I, Crowther AJ, Gama V, Miller CR, Deshmukh
M, Gershon TR. Bax deficiency prolongs cerebellar
neurogenesis, accelerates medulloblastoma formation and
paradoxically increases both malignancy and differentiation.
www.impactjournals.com/Genes&Cancer

69. Yang Z-J, Ellis T, Markant SL, Read T-A, Kessler JD,
Bourboulas M, Schüller U, Machold R, Fishell G, Rowitch
743

Genes & Cancer

DH, Wainwright BJ, Wechsler-Reya RJ. Medulloblastoma
can be initiated by deletion of Patched in lineage-restricted
progenitors or stem cells. Cancer Cell. 2008; 14: 135-45.

Park MJ, Park IC, Lee CT, Kim CM, Hong SI. Growthinhibitory effect of adenovirus-mediated p53 gene transfer
on medulloblastoma cell line, Daoy, harboring mutant
p53. Childs Nerv Syst. 2001; 17: 134-8. doi: 10.1007/
s003810000341.

70. Behesti H, Marino S. Cerebellar granule cells: insights into
proliferation, differentiation, and role in medulloblastoma
pathogenesis. Int J Biochem Cell Biol. 2009; 41: 435-45.

81. Baxter EW, Milner J. p53 Regulates LIF expression in
human medulloblastoma cells. J Neurooncol. 2010; 97:
373-82. doi: 10.1007/s11060-009-0043-x.

71. Nakuci E, Xu M, Pujana MA, Valls J, Elshamy WM.
Geminin is bound to chromatin in G2/M phase to promote
proper cytokinesis. Int J Biochem Cell Biol. 2006; 38:
1207-20. doi: 10.1016/j.biocel.2005.12.017.

82. Ramaswamy V, Nör C, Taylor MD. p53 and
Meduloblastoma. Cold Spring Harbor perspectives in
medicine. 2015; 6. doi: 10.1101/cshperspect.a026278.

72. Klotz-Noack K, McIntosh D, Schurch N, Pratt N, Blow JJ.
Re-replication induced by geminin depletion occurs from
G2 and is enhanced by checkpoint activation. J Cell Sci.
2012; 125: 2436-45. doi: 10.1242/jcs.100883.

83. Zhukova N, Ramaswamy V, Remke M, Pfaff E, Shih DJ,
Martin DC, Castelo-Branco P, Baskin B, Ray PN, Bouffet E,
von Bueren AO, Jones DT, Northcott PA, et al. Subgroupspecific prognostic implications of TP53 mutation in
medulloblastoma. J Clin Oncol. 2013; 31: 2927-35. doi:
10.1200/JCO.2012.48.5052.

73. Liu E, Lee AY, Chiba T, Olson E, Sun P, Wu X. The ATRmediated S phase checkpoint prevents rereplication in
mammalian cells when licensing control is disrupted. J Cell
Biol. 2007; 179: 643-57. doi: 10.1083/jcb.200704138.

84. Spella M, Kyrousi C, Kritikou E, Stathopoulou A,
Guillemot F, Kioussis D, Pachnis V, Lygerou Z, Taraviras
S. Geminin regulates cortical progenitor proliferation
and differentiation. Stem Cells. 2011; 29: 1269-82. doi:
10.1002/stem.678.

74. Davidson IF, Li A, Blow JJ. Deregulated replication
licensing causes DNA fragmentation consistent with headto-tail fork collision. Mol Cell. 2006; 24: 433-43. doi:
10.1016/j.molcel.2006.09.010.

85. von Bueren AO, Shalaby T, Rajtarova J, Stearns D, Eberhart
CG, Helson L, Arcaro A, Grotzer MA. Anti-proliferative
activity of the quassinoid NBT-272 in childhood
medulloblastoma cells. BMC Cancer. 2007; 7: 19. doi:
10.1186/1471-2407-7-19.

75. Green BM, Finn KJ, Li JJ. Loss of DNA replication control
is a potent inducer of gene amplification. Science. 2010;
329: 943-6. doi: 10.1126/science.1190966.
76. Medema RH, Macurek L. Checkpoint control and cancer.
Oncogene. 2012; 31: 2601-13. doi: 10.1038/onc.2011.451.
77. Finn K, Lowndes NF, Grenon M. Eukaryotic DNA damage
checkpoint activation in response to double-strand breaks.
Cell Mol Life Sci. 2012; 69: 1447-73. doi: 10.1007/s00018011-0875-3.
78. Vassilev A, Lee CY, Vassilev B, Zhu W, Ormanoglu P,
Martin SE, DePamphilis ML. Identification of genes that
are essential to restrict genome duplication to once per cell
division. Oncotarget. 2016; 7: 34956-76. doi: 10.18632/
oncotarget.9008.
79. Zhu W, Chen Y, Dutta A. Rereplication by depletion of
geminin is seen regardless of p53 status and activates a
G2/M checkpoint. Mol Cell Biol. 2004; 24: 7140-50.
80. Lee SH, Kang HS, Rhee CH, Kim MS, Kwon HC,

www.impactjournals.com/Genes&Cancer

744

Genes & Cancer

